Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitoxantrone: a replacement for doxorubicin?

C S Conner

    Drug Intelligence & Clinical Pharmacy
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Mitoxantrone, an investigational analog of doxorubicin, was developed to reduce cardiotoxicity in cancer treatment. However, recent studies suggest it may cause similar cardiac adverse effects as doxorubicin, questioning its advancement.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Withered Yang: a review of traditional Chinese medical treatment of male infertility and erectile dysfunction.

    Journal of andrology·2001
    Same author

    Conflicting data in the literature: a true dilemma.

    Drug intelligence & clinical pharmacy·1986
    Same author

    beta-Lactamase inhibitors.

    Drug intelligence & clinical pharmacy·1985
    Same author

    Transdermal nitroglycerin: a reevaluation.

    Drug intelligence & clinical pharmacy·1984
    Same author

    Oral gold in arthritis.

    Drug intelligence & clinical pharmacy·1984
    Same author

    Atracurium and vecuronium: two unique neuromuscular blocking agents.

    Drug intelligence & clinical pharmacy·1984
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Oncology
    • Cardiology
    • Pharmacology

    Background:

    • Doxorubicin (Adriamycin) is a potent anticancer drug, particularly for advanced breast cancer.
    • Doxorubicin's clinical utility is significantly limited by its cardiotoxic effects.
    • Mitoxantrone (Novantrone) was developed as a doxorubicin analog to mitigate cardiotoxicity.

    Purpose of the Study:

    • To evaluate the cardiotoxic potential of mitoxantrone compared to doxorubicin.
    • To determine if mitoxantrone offers a significant advantage in reducing cardiac adverse effects in cancer therapy.

    Main Methods:

    • Review of recent studies investigating mitoxantrone's cardiac effects.
    • Comparison of reported incidences of cardiotoxicity between doxorubicin and mitoxantrone.

    Related Experiment Videos

    Main Results:

    • Initial reports suggested mitoxantrone had low cardiotoxic potential.
    • Recent studies indicate mitoxantrone can cause adverse cardiac effects, including congestive heart failure.
    • The frequency of cardiotoxicity may be similar to that of doxorubicin.

    Conclusions:

    • Mitoxantrone may not represent a significant therapeutic advance over doxorubicin if comparative studies show similar rates of cardiomyopathy.
    • Further direct comparative studies are needed to definitively assess mitoxantrone's cardiotoxic profile relative to doxorubicin.